Summit Therapeutics Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Summit Therapeutics Inc. has filed its annual 10-K report for the fiscal year ended December 31, 2023, detailing its business operations and financial standing.</b>

AI Summary

Summit Therapeutics Inc. (SMMT) filed a Annual Report (10-K) with the SEC on February 20, 2024. Summit Therapeutics Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025. Summit Therapeutics Inc. was formerly known as Summit Therapeutics plc and Summit Corp plc. The filing references various accounting standards, including those related to related party members and impairment of intangible assets.

Why It Matters

For investors and stakeholders tracking Summit Therapeutics Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Summit Therapeutics' financial performance, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current health and future prospects. The detailed financial information and risk factors disclosed in the 10-K are essential for stakeholders to understand the company's financial position, potential risks, and compliance with regulatory requirements.

Risk Assessment

Risk Level: medium — Summit Therapeutics Inc. shows moderate risk based on this filing. The company's financial health and future prospects are subject to the inherent risks of the pharmaceutical industry, including clinical trial success, regulatory approvals, and market competition, as indicated by the filing's nature as a 10-K which typically outlines such factors.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to make informed decisions about their investment in Summit Therapeutics Inc.

Key Numbers

• 2023-12-31 — Fiscal Year End (The end date of the reporting period for the 10-K.)
• 2024-02-20 — Filing Date (The date the 10-K report was filed with the SEC.)

Key Players & Entities

• Summit Therapeutics Inc. (company) — Filer of the 10-K report.
• Summit Therapeutics plc (company) — Former name of the company.
• Summit Corp plc (company) — Former name of the company.
• 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025 (company) — Business address of Summit Therapeutics Inc.

FAQ

Risk Factors

• Regulatory Compliance [medium — regulatory]: The company must comply with various regulations in the pharmaceutical industry, which can impact its operations and product development.
• Financial Stability [medium — financial]: The company's ability to continue as a going concern may depend on its ability to secure future financing and achieve profitability.
• Clinical Trial Risks [high — operational]: The success of the company's drug development programs is subject to the inherent risks and uncertainties of clinical trials.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-02-20: Filing Date — Date the 10-K was officially submitted to the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (Provides a detailed overview of the company's financial health and operations for the fiscal year.)

Fiscal Year End

The last day of a company's accounting year. (Defines the period covered by the financial statements in the 10-K.)

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share SMMT The Nasdaq Stock Market
• $474.9 million — the first quarter of 2023 comprising of $474.9 million cash and the issuance of 10 million sha
• $25.1 million — ares of Company common stock in lieu of $25.1 million cash pursuant to a share transfer agree

Filing Documents

• smmt-20231231.htm (10-K) — 2189KB
• exhibit1051loanagreement.htm (EX-10.51) — 50KB
• sum-ex211_20231231xxsubsid.htm (EX-21.1) — 5KB
• sum-ex231_20231231xxuscons.htm (EX-23.1) — 2KB
• sum-ex311_20231231xduggan.htm (EX-31.1) — 11KB
• sum-ex312_20231231xzanganeh.htm (EX-31.2) — 11KB
• sum-ex313_20231231xdhingra.htm (EX-31.3) — 11KB
• sum-ex321_20231231xx404906.htm (EX-32.1) — 10KB
• ex971summitclawbackpolicy.htm (EX-97.1) — 17KB
• smmt-20231231_g1.jpg (GRAPHIC) — 122KB
• smmt-20231231_g2.jpg (GRAPHIC) — 39KB
• 0001599298-24-000031.txt (&nbsp;) — 10260KB
• smmt-20231231.xsd (EX-101.SCH) — 75KB
• smmt-20231231_cal.xml (EX-101.CAL) — 91KB
• smmt-20231231_def.xml (EX-101.DEF) — 349KB
• smmt-20231231_lab.xml (EX-101.LAB) — 808KB
• smmt-20231231_pre.xml (EX-101.PRE) — 591KB
• smmt-20231231_htm.xml (XML) — 1098KB

Risk Factors

Item 1A. Risk Factors 24

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 57 Item 1C. C ybersecurity 57

Properties

Item 2. Properties 57

Legal Proceedings

Item 3. Legal Proceedings 58

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 58 PART II

Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 59

Selected Financial Data

Item 6. Selected Financial Data 60

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 60

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 74

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 75

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 75

Controls and Procedures

Item 9A. Controls and Procedures 75

Other Information

Item 9B. Other Information 76

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 76 PART III

Directors, Executive Officers, and Corporate Governance

Item 10. Directors, Executive Officers, and Corporate Governance 76

Executive Compensation

Item 11. Executive Compensation 86

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 90

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 92

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 96 PART IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 97

Report Summary

Item 16 Report Summary 102

Signatures

Signatures 103 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding the future financial performance, business prospects and growth of Summit Therapeutics Inc., that involve substantial risks and uncertainties. All statements contained in this Annual Report on Form 10-K, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: the ability to develop a successful product candidate under the License Agreement (as defined in Item I Business, Overview); our ability to raise sufficient additional funds to make payments under the License Agreement; the timing of and the ability to effectively execute clinical development of ivonescimab; the timing and conduct of clinical trials for any product candidates; our plans with respect to possible future collaborations and partnering arrangements; the potential benefits of possible future acquisitions or investments in other businesses, products or technologies; our plans to pursue research and development of other future product candidates; our estimates regarding the potential market opportunity for our product candidates; our sales, marketing an

Business

Item 1. Business Overview Summit Therapeutics Inc. ("we", "Summit" or the "Company") is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company's pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology. The Company's current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the "License Agreement") with Akeso, Inc. and its affiliates ("Akeso") pursuant to which the Company has in-licensed ivonescimab. Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan (the "Licensed Territory"). The License Agreement and transaction closed in January 2023 following customary waiting periods. The Company's operations will be focused on the development of ivonescimab and other future activities, as the Company determines. The Company has begun its development for ivonescimab in non-small cell lung cancer ("NSCLC"), specifically launching Phase III clinical trials in the following indications: a) ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor ("EGFR")-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor ("TKI") ("HARMONi"); and b) ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (

View Full Filing

View this 10-K filing on SEC EDGAR